These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 31147861)

  • 1. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers.
    Zheng L; Wang G; Guo W; Pan D; Xie L; He S; Luo C; Li H; Ran Y; Wu S; Liu F; Zhang X; Huang D
    Mol Biol Rep; 2019 Aug; 46(4):4201-4212. PubMed ID: 31147861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.
    Oh JM; Ahn BC
    Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
    Liu J; Liu Y; Lin Y; Liang J
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
    Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.
    Cai X; Wang R; Tan J; Meng Z; Li N
    Clin Transl Oncol; 2021 Dec; 23(12):2403-2414. PubMed ID: 34100218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
    Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
    [No Abstract]   [Full Text] [Related]  

  • 7. Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.
    Amit M; Na'ara S; Francis D; Matanis W; Zolotov S; Eisenhaber B; Eisenhaber F; Weiler Sagie M; Malkin L; Billan S; Charas T; Gil Z
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
    Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
    Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiated thyroid cancer theranostics: radioiodine and beyond.
    Choudhury PS; Gupta M
    Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells.
    Nikitski AV; Condello V; Divakaran SS; Nikiforov YE
    Thyroid; 2023 Apr; 33(4):464-473. PubMed ID: 36585857
    [No Abstract]   [Full Text] [Related]  

  • 11. Distribution of Na+/I- symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study.
    Mishra A; Pal L; Mishra SK
    World J Surg; 2007 Sep; 31(9):1737-1742. PubMed ID: 17653791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
    Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.
    Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y
    Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model.
    Suzuki K; Iwai H; Utsunomiya K; Kono Y; Watabe T; Kobayashi Y; Bui DV; Sawada S; Yun Y; Mitani A; Fukui K; Sakai H; Chu HH; Linh NM; Tanigawa N; Kanda A
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake.
    Castro MR; Bergert ER; Goellner JR; Hay ID; Morris JC
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5627-32. PubMed ID: 11701745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive role of nontumoral sodium iodide symporter activity and preoperative thyroid characteristics in remission process of thyroid cancer patients.
    Yildirim-Poyraz N; Yazgan A; Ozdemir E; Gozalan A; Keskin M; Ersoy R; Turkolmez S; Cakir B
    Ann Nucl Med; 2014 Aug; 28(7):623-31. PubMed ID: 24823701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of miR-139-5p in radioiodine-resistant thyroid cancer.
    Pecce V; Sponziello M; Verrienti A; Grani G; Abballe L; Bini S; Annunziata S; Perotti G; Salvatori M; Zagaria L; Maggisano V; Russo D; Filetti S; Durante C
    J Endocrinol Invest; 2023 Oct; 46(10):2079-2093. PubMed ID: 36933170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis.
    Wang C; Zhang X; Li H; Li X; Lin Y
    PLoS One; 2017; 12(7):e0179664. PubMed ID: 28704384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy.
    Liu Y; Wang J; Hu X; Pan Z; Xu T; Xu J; Jiang L; Huang P; Zhang Y; Ge M
    Drug Resist Updat; 2023 May; 68():100939. PubMed ID: 36806005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.